Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(122 sites)
United States
Exelixis Clinical Site #67, Phoenix, Arizona Exelixis Clinical Site #1, Tucson, Arizona Exelixis Clinical Site #123, Palo Alto, California Exelixis Clinical Site #59, Santa Barbara, California Exelixis Clinical Site #87, Littleton, Colorado